# Caplyta (lumateperone tosylate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lumateperone

> The FDA approved Caplyta (lumateperone tosylate), sponsored by JOHNSON & JOHNSON (JNJ), on December 20, 2019.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Caplyta (lumateperone tosylate) |
| Codes |  |
| Sponsor | JOHNSON & JOHNSON (JNJ) https://sec-api.dev/companies/jnj/catalysts |
| Indications | [Depressive Disorder, Major](https://sec-api.dev/indications/depressive-disorder-major), [Major Depressive Disorder](https://sec-api.dev/indications/major-depressive-disorder), [Bipolar Disorder, Manic](https://sec-api.dev/indications/bipolar-disorder-manic), [Irritability Associated With Autism Spectrum Disorder](https://sec-api.dev/indications/irritability-associated-with-autism-spectrum-disorder) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### December 20, 2019: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209500 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20191220, review_priority STANDARD; sponsor_name INTRA-CELLULAR; product CAPLYTA (LUMATEPERONE TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209500%22

### December 17, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209500 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20211217, review_priority STANDARD; sponsor_name INTRA-CELLULAR; product CAPLYTA (LUMATEPERONE TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209500%22
- openFDA Drugs@FDA: "NDA209500 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20211217, review_priority STANDARD; sponsor_name INTRA-CELLULAR; product CAPLYTA (LUMATEPERONE TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209500%22

### November 5, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209500 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20251105, review_priority STANDARD; sponsor_name INTRA-CELLULAR; product CAPLYTA (LUMATEPERONE TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209500%22

### February 24, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Bipolar Disorder, Manic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06462586 (Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-24 (ACTUAL); Lead Sponsor Intra-Cellular Therapies, Inc.." https://clinicaltrials.gov/study/NCT06462586

### April 24, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209500 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20260424, review_priority STANDARD; sponsor_name INTRA-CELLULAR; product CAPLYTA (LUMATEPERONE TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209500%22

### May 15, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Bipolar Disorder, Manic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06462612 (Study of Lumateperone in the Treatment of Patients With Bipolar Mania): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-15 (ACTUAL); Lead Sponsor Intra-Cellular Therapies, Inc.." https://clinicaltrials.gov/study/NCT06462612

### Apr to Jul 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Major Depressive Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05850689 (Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-05 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." https://clinicaltrials.gov/study/NCT05850689

### April 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Major Depressive Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05850689 (Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-05 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." https://clinicaltrials.gov/study/NCT05850689

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Irritability Associated With Autism Spectrum Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06690398 (Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." https://clinicaltrials.gov/study/NCT06690398

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Irritability Associated With Autism Spectrum Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06706674 (Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." https://clinicaltrials.gov/study/NCT06706674

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Irritability Associated With Autism Spectrum Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06690398 (Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." https://clinicaltrials.gov/study/NCT06690398

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Irritability Associated With Autism Spectrum Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06706674 (Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." https://clinicaltrials.gov/study/NCT06706674

### Sep to Dec 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Depressive Disorder, Major.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07747389 (A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-09-20 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." https://clinicaltrials.gov/study/NCT07747389

### September 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Depressive Disorder, Major.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07747389 (A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-09-20 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." https://clinicaltrials.gov/study/NCT07747389

## Same indication

- [ALTO-300](https://sec-api.dev/pdufa/alto-300) (ANRO)
- [Azetukalner](https://sec-api.dev/pdufa/azetukalner) (XENE)
- [BHV-7000](https://sec-api.dev/pdufa/bhv-7000) (BHVN)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Evifacotrep](https://sec-api.dev/pdufa/evifacotrep) (BMY)
- [GM-2505](https://sec-api.dev/pdufa/gm-2505) (ABBV)
- [Icalcaprant](https://sec-api.dev/pdufa/icalcaprant) (ABBV)
- [JNJ-89495120](https://sec-api.dev/pdufa/jnj-89495120) (JNJ)
- [Karxt](https://sec-api.dev/pdufa/karxt) (BMY)
- [Lysergide tartrate](https://sec-api.dev/pdufa/lysergide) (DFTX)
- [Navacaprant](https://sec-api.dev/pdufa/navacaprant) (NMRA)
- [NBI-1065845](https://sec-api.dev/pdufa/nbi-1065845) (NBIX)
- [NBI-1070770](https://sec-api.dev/pdufa/nbi-1070770) (NBIX)
- [Psilocybin](https://sec-api.dev/pdufa/psilocybin) (CMPS)
- [Seltorexant](https://sec-api.dev/pdufa/seltorexant) (JNJ)
- [Trintellix (vortioxetine hydrobromide)](https://sec-api.dev/pdufa/vortioxetine) (TAK)

Calendar months: [April 2027](https://sec-api.dev/fda-calendar/2027-04), [June 2027](https://sec-api.dev/fda-calendar/2027-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lumateperone.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Caplyta (lumateperone tosylate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lumateperone

```bibtex
@misc{secapidev_pdufa_lumateperone_20261116,
  title        = {Caplyta (lumateperone tosylate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lumateperone}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lumateperone_20261116","title":"Caplyta (lumateperone tosylate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lumateperone","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
